Company intelligence / Profile preview
Xerient Pharma Ltd.
Israelxerient.net ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Xerient is developing proprietary diagnostic antibodies (XR10/XR15) aiming for early pancreatic cancer detection; company is also repurposing an FDA-approved drug to enhance the safety and efficacy of high-dose radiation therapy in pancreatic cancer. Clinical results are pending; diagnostic product aimed for regulatory approval by mid-2024.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
MD Anderson Cancer CenterCaerus Therapeutics
Beyond the preview
Go deeper on Xerient Pharma Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xerient Pharma Ltd..